ME03775B - Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenjekarboksamida kao aktivni sastojak - Google Patents
Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenjekarboksamida kao aktivni sastojakInfo
- Publication number
- ME03775B ME03775B MEP-2020-77A MEP202077A ME03775B ME 03775 B ME03775 B ME 03775B ME P202077 A MEP202077 A ME P202077A ME 03775 B ME03775 B ME 03775B
- Authority
- ME
- Montenegro
- Prior art keywords
- active ingredient
- medicinal composition
- carboxamide compound
- heterocyclic carboxamide
- diamino heterocyclic
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- -1 heterocyclic carboxamide compound Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019226 | 2014-02-04 | ||
| PCT/JP2015/053018 WO2015119122A1 (ja) | 2014-02-04 | 2015-02-03 | ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物 |
| EP15746276.3A EP3103453B1 (en) | 2014-02-04 | 2015-02-03 | Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03775B true ME03775B (me) | 2021-04-20 |
Family
ID=53777926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-77A ME03775B (me) | 2014-02-04 | 2015-02-03 | Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenjekarboksamida kao aktivni sastojak |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11045468B2 (me) |
| EP (1) | EP3103453B1 (me) |
| JP (1) | JP6390626B2 (me) |
| KR (1) | KR102322338B1 (me) |
| CN (3) | CN116509866A (me) |
| AU (1) | AU2015215578B2 (me) |
| BR (1) | BR112016017897A8 (me) |
| CA (1) | CA2938818C (me) |
| CY (1) | CY1122968T1 (me) |
| DK (1) | DK3103453T3 (me) |
| EA (1) | EA033304B1 (me) |
| ES (1) | ES2788390T3 (me) |
| HR (1) | HRP20200662T1 (me) |
| HU (1) | HUE049437T2 (me) |
| IL (1) | IL247077B (me) |
| LT (1) | LT3103453T (me) |
| ME (1) | ME03775B (me) |
| MX (1) | MX363543B (me) |
| MY (1) | MY193536A (me) |
| PH (1) | PH12016501527A1 (me) |
| PL (1) | PL3103453T3 (me) |
| PT (1) | PT3103453T (me) |
| RS (1) | RS60150B1 (me) |
| SG (1) | SG11201606413RA (me) |
| SI (1) | SI3103453T1 (me) |
| TW (1) | TWI655945B (me) |
| UA (1) | UA120607C2 (me) |
| WO (1) | WO2015119122A1 (me) |
| ZA (1) | ZA201605379B (me) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788390T3 (es) * | 2014-02-04 | 2020-10-21 | Astellas Pharma Inc | Composición médica que comprende un compuesto heterocíclico de diamino-carboxamida como principio activo |
| FI3318259T3 (fi) | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
| US10744134B2 (en) | 2015-11-04 | 2020-08-18 | Astellas Pharma Inc. | Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022220227A1 (ja) * | 2021-04-14 | 2022-10-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロピリドピリミジン化合物 |
| US11945785B2 (en) | 2021-12-30 | 2024-04-02 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of FLT3 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110110923A1 (en) * | 2008-02-12 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Fish assay for eml4 and alk fusion in lung cancer |
| WO2009117097A1 (en) | 2008-03-19 | 2009-09-24 | Chembridge Corporation | Novel tyrosine kinase inhibitors |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| PL2428508T3 (pl) * | 2009-05-08 | 2016-05-31 | Astellas Pharma Inc | Diaminoheterocykliczny związek karboksyamidowy |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| KR20140105765A (ko) * | 2011-11-21 | 2014-09-02 | 이뮤노젠 아이엔씨 | EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법 |
| UA113204C2 (xx) * | 2012-04-02 | 2016-12-26 | Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції | |
| KR20240005211A (ko) * | 2012-11-21 | 2024-01-11 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| ES2788390T3 (es) * | 2014-02-04 | 2020-10-21 | Astellas Pharma Inc | Composición médica que comprende un compuesto heterocíclico de diamino-carboxamida como principio activo |
| WO2015127234A1 (en) | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| FI3318259T3 (fi) * | 2015-07-03 | 2023-03-20 | Astellas Pharma Inc | Stabiili farmaseuttinen koostumus annettavaksi suun kautta |
-
2015
- 2015-02-03 ES ES15746276T patent/ES2788390T3/es active Active
- 2015-02-03 BR BR112016017897A patent/BR112016017897A8/pt active IP Right Grant
- 2015-02-03 JP JP2015560991A patent/JP6390626B2/ja active Active
- 2015-02-03 HU HUE15746276A patent/HUE049437T2/hu unknown
- 2015-02-03 UA UAA201609187A patent/UA120607C2/uk unknown
- 2015-02-03 ME MEP-2020-77A patent/ME03775B/me unknown
- 2015-02-03 DK DK15746276.3T patent/DK3103453T3/da active
- 2015-02-03 AU AU2015215578A patent/AU2015215578B2/en active Active
- 2015-02-03 KR KR1020167022660A patent/KR102322338B1/ko active IP Right Grant
- 2015-02-03 WO PCT/JP2015/053018 patent/WO2015119122A1/ja active Application Filing
- 2015-02-03 CA CA2938818A patent/CA2938818C/en active Active
- 2015-02-03 MY MYPI2016702813A patent/MY193536A/en unknown
- 2015-02-03 CN CN202310702543.7A patent/CN116509866A/zh active Pending
- 2015-02-03 LT LTEP15746276.3T patent/LT3103453T/lt unknown
- 2015-02-03 PL PL15746276T patent/PL3103453T3/pl unknown
- 2015-02-03 SG SG11201606413RA patent/SG11201606413RA/en unknown
- 2015-02-03 EA EA201691570A patent/EA033304B1/ru not_active IP Right Cessation
- 2015-02-03 MX MX2016010134A patent/MX363543B/es unknown
- 2015-02-03 EP EP15746276.3A patent/EP3103453B1/en active Active
- 2015-02-03 SI SI201531179T patent/SI3103453T1/sl unknown
- 2015-02-03 US US15/116,736 patent/US11045468B2/en active Active
- 2015-02-03 CN CN202110880188.3A patent/CN113425727A/zh active Pending
- 2015-02-03 RS RS20200432A patent/RS60150B1/sr unknown
- 2015-02-03 PT PT157462763T patent/PT3103453T/pt unknown
- 2015-02-03 CN CN201580006772.9A patent/CN105939714A/zh active Pending
- 2015-02-04 TW TW104103756A patent/TWI655945B/zh active
-
2016
- 2016-08-02 IL IL247077A patent/IL247077B/en active IP Right Grant
- 2016-08-03 PH PH12016501527A patent/PH12016501527A1/en unknown
- 2016-08-04 ZA ZA2016/05379A patent/ZA201605379B/en unknown
-
2020
- 2020-04-24 HR HRP20200662TT patent/HRP20200662T1/hr unknown
- 2020-04-28 CY CY20201100384T patent/CY1122968T1/el unknown
-
2021
- 2021-05-21 US US17/327,337 patent/US11925638B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1219432A1 (zh) | 以嘧啶化合物爲有效成分的醫藥組合物 | |
| IL247062A0 (en) | Heterocyclic compounds, their preparation and pharmaceutical preparations containing them | |
| ZA201605379B (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| IL253538A0 (en) | Heterocyclic compound and pharmaceutical compound containing it | |
| IL248090A0 (en) | Solid pharmaceutical preparations containing biopterin derivatives and their uses | |
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| IL304109A (en) | Pharmaceutical preparations containing spinamide | |
| HK1243927A1 (zh) | 含有茶皂醇衍生物作爲活性成分的組合物 | |
| IL249010A0 (en) | A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient | |
| SG11201610636VA (en) | Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor | |
| SG11201608845PA (en) | Cosmetic composition containing mentha haplocalyx as active ingredient | |
| EP3372231A4 (en) | PHARMACEUTICAL COMPOSITION FOR ANTICANCER IMMUNOTHERAPY AND / OR FOR IMMUNOSTIMULATION, CONTAINING AS ACTIVE PRINCIPLE A HETEROCYCLIC DIAMINO CARBOXAMIDE COMPOUND | |
| HUE053974T2 (hu) | Szemészeti gyógyászati készítmény | |
| IL252663A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient | |
| EP3120848A4 (en) | Therapeutic/preventive agent containing coumarin derivative as active ingredient | |
| IL252664A0 (en) | A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient | |
| LT3558261T (lt) | Farmacinės kompozicijos, apimančios safinamidą |